Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside - Université d'Angers Accéder directement au contenu
Article Dans Une Revue Autoimmunity Reviews Année : 2020

Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside

Résumé

Anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitides (AAVs) are small vessel vasculitides involving predominantly ear-nose-throat, kidneys, lungs and nerves. AAVs are life-threatening diseases, especially in their most severe forms such as necrotizing crescentic glomerulonephritis (GN) and/or intra-alveolar hemorrhage. Unlike immune complex GN or anti-glomerular basement membrane GN, AAVs are classified as pauci-immune GN. However, based on recent insights from animal models, the view of AAVs as a complement-unrelated disease has been challenged. Indeed, complement activation, and especially complement alternative pathway (cAP) activation, has been shown to be determinant in AAV pathogenesis through C5a generation, a potent chemoattractant for neutrophils with priming capacities. Here, we review in vitro and in vivo data supporting the role of cAP in murine models and in human AAVs. These findings, together with the need to eradicate glucocorticoid toxicity, led to the development of an anti-C5aR molecule, CCX168, also known as avacopan. Its development and future opportunities are also discussed.

Domaines

Cancer
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02519542 , version 1 (26-03-2020)

Identifiants

Citer

Benoit Brilland, Anne-Sophie Garnier, Alain Chevailler, Pascale Jeannin, Jean-François Subra, et al.. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. Autoimmunity Reviews, 2020, 19 (1), pp.102424. ⟨10.1016/j.autrev.2019.102424⟩. ⟨inserm-02519542⟩
50 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More